291 related articles for article (PubMed ID: 30555156)
1. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Nardone A; Weir H; Delpuech O; Brown H; De Angelis C; Cataldo ML; Fu X; Shea MJ; Mitchell T; Veeraraghavan J; Nagi C; Pilling M; Rimawi MF; Trivedi M; Hilsenbeck SG; Chamness GC; Jeselsohn R; Osborne CK; Schiff R
Br J Cancer; 2019 Feb; 120(3):331-339. PubMed ID: 30555156
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER
Robertson JFR; Evans A; Henschen S; Kirwan CC; Jahan A; Kenny LM; Dixon JM; Schmid P; Kothari A; Mohamed O; Fasching PA; Cheung KL; Wuerstlein R; Carroll D; Klinowska T; Lindemann JPO; MacDonald A; Mather R; Maudsley R; Moschetta M; Nikolaou M; Roudier MP; Sarvotham T; Schiavon G; Zhou D; Zhou L; Harbeck N
Clin Cancer Res; 2020 Aug; 26(16):4242-4249. PubMed ID: 32234755
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
5. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
[TBL] [Abstract][Full Text] [Related]
6. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
7. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
9. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
11. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Guan J; Zhou W; Hafner M; Blake RA; Chalouni C; Chen IP; De Bruyn T; Giltnane JM; Hartman SJ; Heidersbach A; Houtman R; Ingalla E; Kategaya L; Kleinheinz T; Li J; Martin SE; Modrusan Z; Nannini M; Oeh J; Ubhayakar S; Wang X; Wertz IE; Young A; Yu M; Sampath D; Hager JH; Friedman LS; Daemen A; Metcalfe C
Cell; 2019 Aug; 178(4):949-963.e18. PubMed ID: 31353221
[TBL] [Abstract][Full Text] [Related]
13. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
14. A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER
Hamilton EP; Patel MR; Armstrong AC; Baird RD; Jhaveri K; Hoch M; Klinowska T; Lindemann JPO; Morgan SR; Schiavon G; Weir HM; Im SA
Clin Cancer Res; 2018 Aug; 24(15):3510-3518. PubMed ID: 29440181
[No Abstract] [Full Text] [Related]
15. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
17. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
18. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
Borley AC; Hiscox S; Gee J; Smith C; Shaw V; Barrett-Lee P; Nicholson RI
Breast Cancer Res; 2008; 10(6):R103. PubMed ID: 19055788
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Simigdala N; Pancholi S; Ribas R; Folkerd E; Liccardi G; Nikitorowicz-Buniak J; Johnston SR; Dowsett M; Martin LA
Br J Cancer; 2018 Aug; 119(3):313-322. PubMed ID: 29991699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
